AZD8683 Single Ascending Dose Study

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Volunteers

In brief

The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8683 following single ascending dose administrations in healthy male subjects.

Key facts

Study ID

NCT00979849

Run by

AstraZeneca

People needed

130

Starts

2009-10-01

Expected to finish

2010-01-01

Last updated by the study team

2010-03-02

Who can join

Age: 18 and older, up to 45. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Provision of signed, written and dated informed consent prior to any study specific procedures
• Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg
• Be non-smoker or ex-smoker who has stopped smoking (or using other nicotine products) for >6 months prior to study start

You may not qualify if…

• Any clinically significant disease or disorder
• Any clinically significant abnormalities at screening examinations
• Use any prescribed or non-prescribed medication

Where it is running

• Research Site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.